Overviewing Cardiac Safety Profile of Vildagliptin 100mg SR -ft-Prof. Dr Aravinda Jagadeesha

Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-12-05 06:30 GMT   |   Update On 2023-05-03 07:28 GMT

Vildagliptin has established itself over the years by controlling the blood sugar levels in patients with type 2 diabetes mellitus. It is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It also displays significant HbA1c lowering and has a low risk of edema, as well as that of hypoglycemia. These characteristic features make vildagliptin a favorable partner for combination therapy as well as newer formulations like sustained release.

In this video, Prof. Dr Aravinda Jagadeesha, a diabetologist and the chairman at Dr. Aravinds Diabetes Centre in Bengaluru, India talks about how Vildagliptin and how it has proven itself in the past 15 years. In particular, Dr Jagadeesha provides his viewpoints on the cardiac safety profile of Vildagliptin 100mg SR.
In the case of Cardiovascular Safety, Vildagliptin has a plethora of studies including 3 Real-world studies, 3 Meta-analyses, and 1 RCT, establishing safety in over 10 lakh patients. The studies demonstrated that Vildagliptin is not associated with increased Cardiovascular risk, including the risk of Chronic Heart Failure. Even a thorough QT study demonstrated that Vildagliptin has no prolonged QT interval or effect on cardiac conduction even at the highest daily therapeutic dose.
Full View
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News